Overview

Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia

Status:
Recruiting
Trial end date:
2023-12-20
Target enrollment:
Participant gender:
Summary
Phase 3 study to evaluate the safety and effectiveness of LNZ101 for the treatment of Presbyopia.
Phase:
Phase 3
Details
Lead Sponsor:
LENZ Therapeutics, Inc
Collaborator:
ORA, Inc.
Treatments:
Aceclidine
Brimonidine Tartrate